Trialjectory, foundation to connect blood cancer patients with trials
Trialjectory has announced a collaboration with the MPN Research Foundation, aimed at helping bring patients with rare blood cancers and studies in need of patients together.
MPNRF supports research into treatments for myeloproliferative neoplasms (MPNs), a set of rare blood cancers that includes essential thrombocythemia, polycythemia vera, and myelofibrosis. Trialjectory has signed up to provide the MPNRF community with its free, AI-powered clinical trial finder in a deal that could bring benefits to oncology drug developers.
“This partnership will provide pharmaceutical companies with robust data and insights as a result of these patients’ participation and screenings in these clinical trials. At Trialjectory, our goal is to transform the healthcare industry and its approach to patient-centricity. By supporting enrollment in clinical trials, the pharmaceutical companies are able to examine more patient data to improve the standard of care and, in turn, create better clinical outcomes for patients,” said Trialjectory CEO Tzvia Bader.
The clinical trial finder uses self-reported questionnaire results to provide each MPN patient with a list of studies that match their specific cancer type. Trialjectory also provides a concierge service, at no cost to patients, that enables potential study participants to get questions answered and connect directly with staff at the clinical trial site of interest.
MPNRF CEO Kapila Viges sees Trialjectory’s capabilities as a good fit for the needs of patients with myeloproliferative neoplasms.
“MPN patients are seeking treatment options for this family of rare blood diseases, and MPN clinical trials need patients to complete the trials with enough outcomes to demonstrate they could be made available to all patients. By providing an MPN clinical trial platform powered by Trialjectory, MPNRF can now deliver up-to-date information on clinical trials,” Viges said.
Patients with other cancers have similar needs. Trialjectory already provides the patient match optimizer to patients with other cancers and sees the agreement with MPNRF as a model it can apply to other disease areas in the future.
“Working with partners to bring their patients easy access to advanced treatment options on the sites that they are already visiting is just another streamlined efficiency we can ensure in order to eliminate stress in an already difficult time. The biggest obstacle that both oncologists and patients face is the knowledge and access to clinical trial matching. Through Trialjectory’s clinical trial finder, the process for patients is simplified,” said Bader.
